Table 4.
Change in clinical parameters and diabetes treatment of people with type 2 diabetes during COVID-19 pandemic (N = 206).
| Clinical parameters | Mean ± SD |
||
|---|---|---|---|
| Before COVID-19 | During COVID-19 | P | |
| HbA1c (%) | 8.2 ± 1.9 | 8.0 ± 1.7 | 0.080 |
| LDL (mg/dL) | 76.7 ± 31.1 | 74.7 ± 30.0 | 0.264 |
| Total cholesterol (mg/dL) | 151.3 ± 37.4 | 149.4 ± 37.4 | 0.830 |
| Serum creatinine (mg/dL) | 0.9 ± 1.0 | 0.9 ± 1.1 | 0.996 |
| Urinary albumin (mg) | 62.8 ± 146.1 | 73.4 ± 173.7 | 0.077 |
| BMI (kg/m2) | 31.1 ± 5.9 | 31.0 ± 6.0 | 0.609 |
| Diabetes treatment before COVID-19 | n (%) | ||
| Combination of OHA/insulin/GLP-1 receptor agonist | 97 (47.1) | ||
| OHA only | 83 (40.3) | ||
| Insulin only | 16 (7.8) | ||
| GLP-1 receptor agonist only | 3 (1.5) | ||
| Diet alone | 1 (0.5) | ||
| Diabetes treatment modification during COVID-19 | n (%) | ||
| No modifications | 150 (72.8) | ||
| Treatment modified | 51 (25.0) | ||
| Treatment intensified | 44 (86.3) | ||
| Treatment de-intensified | 6 (11.8) | ||
| Types of treatment modification | |||
| Insulin added/switched to insulin | 7 (13.7) | ||
| Insulin regimen intensified | 28 (54.9) | ||
| Insulin regimen de-intensified/discontinued | 4 (7.8) | ||
| OHA added | 7 (13.7) | ||
| OHA dose decreased/OHA discontinued | 4 (7.8) | ||
| GLP-1 receptor agonist added | 2 (3.9) | ||
*LDL: Low density lipoprotein cholesterol; BMI: Body mass index; OHA: Oral hypoglycemic agent(s); GLP-1: glucagon-like peptide-1.